Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C.

Ingelsson B, Söderberg D, Strid T, Söderberg A, Bergh AC, Loitto V, Lotfi K, Segelmark M, Spyrou G, Rosén A.

Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E478-E487. doi: 10.1073/pnas.1711950115. Epub 2018 Jan 2.

2.

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.

Jakobsen Falk I, Lund J, Gréen H, Gruber A, Alici E, Lauri B, Blimark C, Mellqvist UH, Swedin A, Forsberg K, Carlsson C, Hardling M, Ahlberg L, Lotfi K, Nahi H.

Cancer Chemother Pharmacol. 2018 Jan;81(1):183-193. doi: 10.1007/s00280-017-3481-8. Epub 2017 Nov 25.

3.

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.

Rajala HLM, Missiry ME, Ruusila A, Koskenvesa P, Brümmendorf TH, Gjertsen BT, Janssen J, Lotfi K, Markevärn B, Olsson-Strömberg U, Stenke L, Stentoft J, Richter J, Hjorth-Hansen H, Kreutzman A, Mustjoki S.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1543-1554. doi: 10.1007/s00432-017-2378-6. Epub 2017 Mar 23.

PMID:
28337541
4.

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S, Höglund M, Markevärn B, Själander A, Lotfi K, Dreimane A, Lübking A, Holm E, Björeman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S.

Leukemia. 2017 May;31(5):1108-1116. doi: 10.1038/leu.2016.360. Epub 2016 Nov 28.

5.

PO-55 - Individual variation in hemostatic alterations caused by tyrosine kinase inhibitors - a way to improve personalized cancer therapy?

Deb S, Sjöström C, Tharmakulanathan A, Boknäs N, Lotfi K, Ramström S.

Thromb Res. 2016 Apr;140 Suppl 1:S196-7. doi: 10.1016/S0049-3848(16)30188-8. Epub 2016 Apr 8.

PMID:
27161743
6.

Single Nucleotide Polymorphisms in MORC4, CD14, and TLR4 Are Related to Outcome of Allogeneic Stem Cell Transplantation.

Norén E, Verma D, Söderkvist P, Weisselberg T, Söderman J, Lotfi K, Almer S.

Ann Transplant. 2016 Jan 31;21:56-67.

7.

In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.

Skoglund K, Richter J, Olsson-Strömberg U, Bergquist J, Aluthgedara W, Ubhayasekera SJ, Vikingsson S, Svedberg A, Söderlund S, Sandstedt A, Johnsson A, Aagesen J, Alsenhed J, Hägg S, Peterson C, Lotfi K, Gréen H.

Ther Drug Monit. 2016 Apr;38(2):230-8. doi: 10.1097/FTD.0000000000000268.

8.

Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.

Mosrati MA, Willander K, Falk IJ, Hermanson M, Höglund M, Stockelberg D, Wei Y, Lotfi K, Söderkvist P.

Oncotarget. 2015 Sep 22;6(28):25109-20. doi: 10.18632/oncotarget.4668.

9.

Nucleoside Analog Activity in Malignant Melanoma Cell Lines.

Fyrberg A, Lotfi K.

Nucleosides Nucleotides Nucleic Acids. 2015;34(9):639-49. doi: 10.1080/15257770.2015.1047029.

PMID:
26252632
10.

Frequent and long-term follow-up of health-related quality of life following allogeneic haematopoietic stem cell transplantation.

Frödin U, Lotfi K, Fomichov V, Juliusson G, Börjeson S.

Eur J Cancer Care (Engl). 2015 Nov;24(6):898-910. doi: 10.1111/ecc.12350. Epub 2015 Jul 7.

11.

Glucose starvation-mediated inhibition of salinomycin induced autophagy amplifies cancer cell specific cell death.

Jangamreddy JR, Jain MV, Hallbeck AL, Roberg K, Lotfi K, Łos MJ.

Oncotarget. 2015 Apr 30;6(12):10134-45.

12.

Case Study: Weight loss in a patient with type 2 diabetes: Challenges of diabetes management.

Lotfi K, Palmer K, Apovian CM.

Obesity (Silver Spring). 2015 Apr;23 Suppl 1:S11-2. doi: 10.1002/oby.21095.

13.

Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia.

Willander K, Falk IJ, Chaireti R, Paul E, Hermansson M, Gréen H, Lotfi K, Söderkvist P.

Biomark Res. 2014 Oct 8;2:18. doi: 10.1186/2050-7771-2-18. eCollection 2014.

14.

Mapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy.

Jangamreddy JR, Panigrahi S, Lotfi K, Yadav M, Maddika S, Tripathi AK, Sanyal S, Łos MJ.

Oncotarget. 2014 Aug 30;5(16):7198-211.

15.

TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.

Falk IJ, Willander K, Chaireti R, Lund J, Nahi H, Hermanson M, Gréen H, Lotfi K, Söderkvist P.

Eur J Haematol. 2015 Apr;94(4):355-62. doi: 10.1111/ejh.12438. Epub 2014 Oct 1.

16.

Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype.

Jakobsen Falk I, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K.

Br J Haematol. 2014 Dec;167(5):671-80. doi: 10.1111/bjh.13097. Epub 2014 Aug 23.

17.

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Höglund M, Koskenvesa P, Lotfi K, Majeed W, Markevärn B, Ohm L, Olsson-Strömberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J; Nordic CML Study Group.

Eur J Haematol. 2015 Mar;94(3):243-50. doi: 10.1111/ejh.12423. Epub 2014 Sep 13.

18.

Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Richter J, Söderlund S, Lübking A, Dreimane A, Lotfi K, Markevärn B, Själander A, Saussele S, Olsson-Strömberg U, Stenke L.

J Clin Oncol. 2014 Sep 1;32(25):2821-3. doi: 10.1200/JCO.2014.55.6910. Epub 2014 Jul 28. No abstract available.

PMID:
25071107
19.

Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.

Falk IJ, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K.

Am J Hematol. 2013 Dec;88(12):1001-6. doi: 10.1002/ajh.23549. Epub 2013 Sep 9.

20.

A potential role of fetal hemoglobin in the development of multidrug resistance.

Fyrberg A, Skoglund K, Wolk M, Lotfi K.

Biochem Biophys Res Commun. 2012 Oct 26;427(3):456-60. doi: 10.1016/j.bbrc.2012.07.129. Epub 2012 Aug 11.

PMID:
22910410
21.

Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.

Nordigården A, Zetterblad J, Trinks C, Gréen H, Eliasson P, Druid P, Lotfi K, Rönnstrand L, Walz TM, Jönsson JI.

Br J Haematol. 2011 Oct;155(2):198-208. doi: 10.1111/j.1365-2141.2011.08819.x. Epub 2011 Aug 16.

PMID:
21848891
22.

A prospective evaluation of patients' health-related quality of life during auto-SCT: a 3-year follow-up.

Frödin U, Börjeson S, Lyth J, Lotfi K.

Bone Marrow Transplant. 2011 Oct;46(10):1345-52. doi: 10.1038/bmt.2010.304. Epub 2010 Nov 29.

PMID:
21113189
23.

Induction of fetal hemoglobin and ABCB1 gene expression in 9-β-D-arabinofuranosylguanine-resistant MOLT-4 cells.

Fyrberg A, Peterson C, Kågedal B, Lotfi K.

Cancer Chemother Pharmacol. 2011 Sep;68(3):583-91. doi: 10.1007/s00280-010-1524-5. Epub 2010 Nov 26.

PMID:
21110023
24.

Optimization and evaluation of electroporation delivery of siRNA in the human leukemic CEM cell line.

Fyrberg A, Lotfi K.

Cytotechnology. 2010 Dec;62(6):497-507. doi: 10.1007/s10616-010-9309-6. Epub 2010 Oct 19.

25.

Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype.

Gréen H, Falk IJ, Lotfi K, Paul E, Hermansson M, Rosenquist R, Paul C, Nahi H.

Pharmacogenomics J. 2012 Apr;12(2):111-8. doi: 10.1038/tpj.2010.79. Epub 2010 Oct 12.

PMID:
20938465
26.

Enhanced platelet adhesion in essential thrombocythemia after in vitro activation.

Eriksson AC, Lotfi K, Whiss PA.

Turk J Haematol. 2010 Jun 5;27(2):82-90. doi: 10.5152/tjh.2010.05.

27.

Platelet density distribution in essential thrombocythemia.

Milovanovic M, Lotfi K, Lindahl T, Hallert C, Järemo P.

Pathophysiol Haemost Thromb. 2010;37(1):35-42. doi: 10.1159/000314964. Epub 2010 May 19.

28.

[Drug-induced liver injury from the dietary supplement Fortodol. A manipulated preparation delayed the diagnosis].

Kechagias S, Hägg S, Lotfi K.

Lakartidningen. 2010 Jan 27-Feb 2;107(4):186-8. Swedish. No abstract available.

PMID:
20333973
29.

CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity.

Gréen H, Skoglund K, Rommel F, Mirghani RA, Lotfi K.

Eur J Clin Pharmacol. 2010 Apr;66(4):383-6. doi: 10.1007/s00228-009-0772-y.

PMID:
20054526
30.

Mechanisms of anti-cancer action and pharmacology of clofarabine.

Zhenchuk A, Lotfi K, Juliusson G, Albertioni F.

Biochem Pharmacol. 2009 Dec 1;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094. Epub 2009 Jul 1. Review.

PMID:
19576186
31.

RNAi depletion of deoxycytidine and deoxyguanosine kinase in human leukemic CEM cells.

Fyrberg A, Albertioni F, Lotfi K.

Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):712-9. doi: 10.1080/15257770802145231.

PMID:
18600530
32.

Cardiac arrest in schools.

Lotfi K, White L, Rea T, Cobb L, Copass M, Yin L, Becker L, Eisenberg M.

Circulation. 2007 Sep 18;116(12):1374-9. Epub 2007 Aug 27.

PMID:
17724258
33.

Cell cycle effect on the activity of deoxynucleoside analogue metabolising enzymes.

Fyrberg A, Albertioni F, Lotfi K.

Biochem Biophys Res Commun. 2007 Jun 15;357(4):847-53. Epub 2007 Apr 9.

PMID:
17459340
34.

Cell cycle dependent regulation of deoxycytidine kinase, deoxyguanosine kinase, and cytosolic 5'-nucleotidase I activity in MOLT-4 cells.

Fyrberg A, Mirzaee S, Lotfi K.

Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1201-4.

PMID:
17065091
35.

The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia.

Lotfi K, Karlsson K, Fyrberg A, Juliusson G, Jonsson V, Peterson C, Eriksson S, Albertioni F.

Biochem Pharmacol. 2006 Mar 14;71(6):882-90. Epub 2006 Jan 24.

PMID:
16436271
36.

Monitoring oral cyclosporine therapy.

Lotfi K, Peterson C, Juliusson G.

Bone Marrow Transplant. 2005 Aug;36(4):367. No abstract available.

PMID:
15968286
37.

Mechanisms of cross-resistance between nucleoside analogues and vincristine or daunorubicin in leukemic cells.

Löfgren C, Hjortsberg L, Blennow M, Lotfi K, Paul C, Eriksson S, Albertioni F.

Biochem Biophys Res Commun. 2004 Jul 30;320(3):825-32.

PMID:
15240122
38.

Pharmacological basis for cladribine resistance.

Lotfi K, Juliusson G, Albertioni F.

Leuk Lymphoma. 2003 Oct;44(10):1705-12. Review.

PMID:
14692522
39.

Spontaneous reversal of p-glycoprotein expression in multidrug resistant cell lines.

Gréen H, Lotfi K, Zackrisson AL, Peterson C.

Pharmacol Toxicol. 2003 Dec;93(6):297-304.

PMID:
14675464
40.

Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity.

Lotfi K, Månsson E, Peterson C, Eriksson S, Albertioni F.

Biochem Biophys Res Commun. 2002 May 24;293(5):1489-96.

PMID:
12054684
41.

Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.

Lotfi K, Zackrisson AL, Peterson C.

Cancer Lett. 2002 Apr 25;178(2):141-9.

PMID:
11867198
42.

Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide.

Lotfi K, Månsson E, Chandra J, Wang Y, Xu D, Knaust E, Spasokoukotskaja T, Liliemark E, Eriksson S, Albertioni F.

Br J Haematol. 2001 May;113(2):339-46.

PMID:
11380397
43.

Unsuspected lymphoma detected on Tc-99m sestamibi parathyroid scan.

Thomas RJ, Joyce JM, Myers DT, Lotfi K, Organist M.

Clin Nucl Med. 2000 Sep;25(9):716-8. No abstract available.

PMID:
10983761
44.

Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.

Lotfi K, Månsson E, Spasokoukotskaja T, Pettersson B, Liliemark J, Peterson C, Eriksson S, Albertioni F.

Clin Cancer Res. 1999 Sep;5(9):2438-44.

45.

The beta cell glucokinase promoter variant is an unlikely risk factor for diabetes mellitus. Diabetes Incidence Study in Sweden (DISS).

Lotfi K, Sund G, Lowe R, Graham J, Landin-Olsson M, Kockum I, Deeb S, Lernmark A.

Diabetologia. 1997 Aug;40(8):959-62.

PMID:
9267992
46.
47.

Determination of meropenem in plasma by high-performance liquid chromatography and a microbiological method.

al-Meshal MA, Ramadan MA, Lotfi KM, Shibl AM.

J Clin Pharm Ther. 1995 Jun;20(3):159-63.

PMID:
7593377
48.

The effect of caffeine on the human macular circulation.

Lotfi K, Grunwald JE.

Invest Ophthalmol Vis Sci. 1991 Nov;32(12):3028-32.

PMID:
1938279

Supplemental Content

Support Center